JLE

Innovations & Thérapeutiques en Oncologie

MENU

Targeting of NF-kappaB in oncology Volume 4, issue 5-6, September-December 2018

Figures


  • Figure 1

  • Figure 2

  • Figure 3

Tables

Authors
“NF-κB, Différentiation et Cancer”
Université Paris Descartes
Sorbonne Paris Cité
France
* Tirés à part

Although mortality rates have declined in recent years, the majority of cancers are still difficult to treat and the medical need for better cancer treatment is evident. The current anticancer armamentarium includes many active agents that are applied across tumor types. However most of these broadly active anticancer drugs have a small therapeutic index and barely discriminate between malignant and normal cells. In recent years the focus has shifted to the development of rationally designed, molecularly-targeted therapy for the treatment of a specific cancer, therefore offering the promise of greater specificity coupled with reduced systemic toxicity. NF-κB transcription factor family as emerged as such a promising target for cancer therapy. Our article explores the routes to the current development of NF-κB-based cancer therapeutics.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License